Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: Subanalysis of the EMPA-REG OUTCOME randomised trial
Diabetologia - Clinical and Experimental Diabetes and Metabolism | Jul 11, 2018
Psoriasis, metabolic syndrome and cardiovascular risk factors: A population-based study
Journal of the European Academy of Dermatology and Venereology | Jul 11, 2018
Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: A double-blind randomised placebo-controlled study
Diabetologia - Clinical and Experimental Diabetes and Metabolism | Jul 10, 2018
Most read this week